Evidence map›Paper›PMID 39840213›Full record

ArticleCureus2024

A Case of Severe Lupus and Refractory Anemia.

Isabel Bessa, Elisabete Ribeiro, Teresa Frazão, Anabela De Carvalho, Carlos Fernandes

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Isabel BessaInternal Medicine, Hospital da Senhora da Oliveira, Guimarães, PRT.
Elisabete RibeiroInternal Medicine, Hospital da Senhora da Oliveira, Guimarães, PRT.
Teresa FrazãoInternal Medicine, Hospital da Senhora da Oliveira, Guimarães, PRT.
Anabela De CarvalhoInternal Medicine, Hospital da Senhora da Oliveira, Guimarães, PRT.
Carlos FernandesInternal Medicine, Hospital da Senhora da Oliveira, Guimarães, PRT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a multisystemic connective tissue disease with a wide range of clinical and laboratory manifestations. The diagnosis of SLE is often challenging due to the great variability in its presentation, and treatment should be individualized according to the patient's manifestations and affected organs. We present the clinical case of a 25-year-old female who developed SLE with severe hematological and renal involvement as first manifestations, including hemolytic anemia, thrombocytopenia, and nephrotic syndrome. Diagnosis of SLE was confirmed after positive high titers of ANA and anti-dsDNA antibodies. A kidney biopsy confirmed lupus nephritis class II.  Despite successive treatment with corticosteroids, hydroxychloroquine, intravenous immunoglobulin, and mycophenolate mofetil, there was no hematological improvement, and rituximab was administered, resulting in partial response, with resolution of thrombocytopenia and stabilization of kidney function. However, anemia remained refractory, and subsequent tests indicated a non-hemolytic cause, most likely due to iatrogenic bone marrow suppression. After discontinuing potentially myelotoxic agents, the patient's hemoglobin levels normalized. This case highlights the intricate challenges associated with managing SLE. It underscores the critical importance of ongoing reassessment of therapeutic strategies, particularly in situations where the treatment response is inadequate. This approach enables the optimization of interventions to improve clinical outcomes and address the unique needs of each patient.

Indexed as

hemolytic anemialupuslupus nephritisnephrotic syndromethrombocytopenia

Identifiers

PMID39840213
PMCPMC11745837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.